The FDA has approved a groundbreaking new therapy for patients battling late-stage melanoma, offering hope when options run out.

Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus (EBV)-driven lymphomas. The findings, ...

Chinese women aged 65 years or older have significantly higher rates of high-risk human papillomavirus infection and cervical ...